Related Experiment Videos
A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance
W Andrivon1, C Monneret, J Nafziger
1Laboratoire d'Hématologie Cellulaire et Moléculaire, EA 1509, UFR des Sciences Pharmaceutiques et Biologiques, Paris, France.
Abstract:
In this study, we assessed the ability of a new anthracycline, moflomycin, to circumvent multidrug resistance. Moflomycin showed superior anti-proliferative activity compared to daunorubicin and doxorubicin on two resistant cell lines: leukemic HL-60 cell line resistant to daunorubicin (HL-60/DR) and breast cancerous cell line resistant to doxorubicin (MCF-7/AR). The effect of moflomycin on cell proliferation was correlated with an increased uptake and a decreased cellular efflux. The data obtained in the presence of the P-gp inhibitor, verapamil, confirmed the absence of interaction between P-gp and moflomycin. Our results indicate that moflomycin exhibits an important reduction in cross-resistance with daunorubicin and doxorubicin resulting from its ability to circumvent P-gp.
Insights
Moflomycin, a novel anthracycline, effectively combats multidrug resistance in cancer cells. It demonstrates superior anti-proliferative effects by overcoming resistance mechanisms, unlike older drugs.
Area of Science:
- Pharmacology
- Oncology
- Molecular Biology
Background:
- Multidrug resistance (MDR) is a major challenge in cancer chemotherapy, limiting the efficacy of anthracyclines like daunorubicin and doxorubicin.
- P-glycoprotein (P-gp) is a key efflux pump contributing to MDR by reducing intracellular drug accumulation.
Purpose of the Study:
- To evaluate the efficacy of moflomycin, a new anthracycline, in circumventing MDR.
- To compare moflomycin's anti-proliferative activity against daunorubicin and doxorubicin in resistant cancer cell lines.
Main Methods:
- Assessed anti-proliferative activity of moflomycin, daunorubicin, and doxorubicin on HL-60/DR and MCF-7/AR cell lines.
- Investigated drug uptake and efflux of moflomycin.
- Evaluated moflomycin's interaction with P-gp using verapamil, a P-gp inhibitor.
Main Results:
- Moflomycin exhibited superior anti-proliferative activity compared to daunorubicin and doxorubicin in both resistant cell lines.
- Moflomycin's efficacy was associated with increased cellular uptake and decreased drug efflux.
- Absence of interaction between moflomycin and P-gp was confirmed in the presence of verapamil.
Conclusions:
- Moflomycin effectively circumvents P-gp-mediated multidrug resistance.
- Moflomycin demonstrates reduced cross-resistance with daunorubicin and doxorubicin, offering a promising alternative for MDR cancer treatment.